What is the cause of recurrent kidney stones in a patient on long‑term hydrochlorothiazide therapy?

Recurrent Kidney Stones Despite Long-Term Hydrochlorothiazide Therapy

The most likely causes of recurrent stones in a patient on long-term HCTZ are inadequate dietary sodium restriction, insufficient fluid intake, thiazide-induced hypocitraturia from hypokalemia, or the presence of metabolic abnormalities beyond hypercalciuria that HCTZ does not address.

Primary Mechanisms of Treatment Failure

Dietary Non-Adherence Undermining HCTZ Efficacy

The hypocalciuric effect of thiazides is critically dependent on concurrent sodium restriction 1. High dietary sodium intake directly counteracts HCTZ's calcium-lowering effect by increasing urinary calcium excretion, essentially negating the therapeutic benefit. The AUA guidelines explicitly state that "dietary prescription, especially restriction of sodium intake, should be continued when thiazides are prescribed, in order to maximize the hypocalciuric effect" 1.

Recent evidence from the NOSTONE trial 2 suggests poor dietary adherence (particularly regarding oxalate and salt consumption) may have contributed to treatment failure, potentially mitigating HCTZ's beneficial hypocalciuric effect 3.

Thiazide-Induced Metabolic Complications

Hypokalemia and subsequent hypocitraturia represent a critical mechanism of treatment failure. HCTZ causes potassium wasting, which can lead to:

• Hypocitraturia: Low potassium reduces urinary citrate excretion, eliminating a key stone inhibitor 1
• Metabolic acidosis: Further reduces citrate excretion

The AUA guidelines specifically note that "potassium supplementation (either potassium citrate or chloride) may be needed when thiazide therapy is employed" and that "the addition of amiloride or potassium citrate therapy have been shown to prevent recurrent stones in patients with normal range urinary calcium and citrate, respectively" 1.

Insufficient Dosing

The evidence suggests that lower doses of HCTZ may be inadequate. While the recent NOSTONE trial 2 showed no overall benefit at any dose (12.5,25, or 50 mg daily), a 2025 network meta-analysis 4 found that only hydrochlorothiazide 50 mg/d was statistically different from placebo (OR: 0.52,95% CI 0.29-0.93). Another 2025 meta-analysis 5 specifically recommended "a daily dose of 50 mg of hydrochlorothiazide for 36 months" for optimal efficacy.

The AUA guidelines recommend doses of 25 mg twice daily or 50 mg once daily 1, which are higher than commonly prescribed maintenance doses.

Unaddressed Metabolic Abnormalities

HCTZ only addresses hypercalciuria—it does not treat other lithogenic factors:

• Hyperuricosuria: Requires allopurinol (if urinary uric acid >800 mg/day with normocalciuria) 1
• Low urinary pH: Promotes uric acid stone formation; requires alkalinization with potassium citrate 1
• Hyperoxaluria: Requires dietary oxalate restriction
• Low urine volume: Requires increased fluid intake to achieve ≥2L urine output daily 6

The AUA guidelines state that thiazides and/or potassium citrate should be offered "to patients with recurrent calcium stones in whom other metabolic abnormalities are absent or have been appropriately addressed and stone formation persists" 1.

Diagnostic Approach

Obtain a 24-hour urine collection to identify the specific metabolic defect(s):

• Urinary calcium (assess HCTZ efficacy and dietary sodium compliance)
• Urinary citrate (assess for thiazide-induced hypocitraturia)
• Urinary uric acid (assess for hyperuricosuria)
• Urinary oxalate (assess dietary compliance)
• Urine volume (assess fluid intake adequacy)
• Urinary pH (assess for acidic urine promoting uric acid stones)
• Urinary sodium (directly assess dietary sodium intake)

Check serum electrolytes:

• Potassium (assess for hypokalemia)
• Calcium (assess for hypercalcemia suggesting hyperparathyroidism)

Management Algorithm

1. Verify and optimize dietary compliance:

   • Sodium restriction to <100 mEq (2,300 mg) daily 1
   • Fluid intake to achieve ≥2L urine output 6
   • Normal dietary calcium (do not restrict)
   • Limit animal protein

2. Address thiazide-induced complications:

   • Add potassium citrate if hypokalemia or hypocitraturia present 1
   • Consider amiloride as alternative to potassium supplementation 1

3. Optimize HCTZ dosing:

   • Increase to 50 mg daily if currently on lower dose 5
   • Consider chlorthalidone 25 mg daily as alternative (longer half-life, potentially more effective) 1

4. Add targeted therapy for other metabolic abnormalities:

   • Allopurinol if hyperuricosuria (>800 mg/day) with normocalciuria 1
   • Potassium citrate if hypocitraturia or low urinary pH 1

Critical Caveats

Recent high-quality evidence challenges routine HCTZ use. The 2023 NOSTONE trial 2—the largest randomized controlled trial to date—found no significant difference in stone recurrence between HCTZ (at any dose up to 50 mg) and placebo, while adverse events (hypokalemia, gout, new-onset diabetes, skin allergy) were more common with HCTZ. A 2024 meta-analysis 7 and 2025 network meta-analysis 4 similarly concluded that current evidence does not support routine thiazide use for all stone formers.

However, these trials included patients without documented hypercalciuria 3, which may have underestimated HCTZ efficacy in the specific population for which it was intended. The AUA guidelines 1 specifically recommend thiazides for patients with "high or relatively high urine calcium," not for all stone formers.

Therefore, HCTZ should be reserved for patients with documented hypercalciuria on 24-hour urine collection, combined with aggressive dietary sodium restriction and potassium supplementation/citrate therapy to maximize efficacy and minimize harm.